EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 364 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... September 1, 2022 FDA Says Breast Implant Cancer Risk Is Not Enough to Warrant... May 3, 2019 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 Load more HOT NEWS FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric... Doing More—Together—to End Cancer as We Know It
